Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134 AF , a pan-ebolavirus therapeutic comprising two broadly neutralizing human antibodies (bNAbs), affords unprecedented effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses. MBP134 AF could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg dose was sufficient to protect NHPs against all three viruses. The development of MBP134 AF provides a successful model for the rapid discovery and translational advancement of immunotherapeutics targeting emerging infectious diseases.
In Brief Bornholdt et al. examine the therapeutic efficacy of MBP134 AF , a pan-ebolavirus cocktail comprising two human mAbs. MBP134 AF reverted lethal disease in both ferret and nonhuman primates challenged with three divergent ebolaviruses. A single dose of MBP134 AF administered post-infection was sufficient to protect nonhuman primates from ebolavirus disease.
INTRODUCTION
The 2013-2016 Ebola virus (EBOV) epidemic in Western Africa and the recent EBOV outbreaks in the Democratic Republic of Congo have established ebolaviruses as pathogens of global public health relevance. Of the five ebolaviruses known to infect humans, EBOV, Sudan virus (SUDV), and Bundibugyo virus (BDBV) have caused outbreaks with case-fatality rates up to 90% in the last decade (Burk et al., 2016) . Although several therapeutic products are in clinical development for the treatment of Ebola virus disease (EVD), no medical countermeasures to SUDV or BDBV have progressed beyond proof-of-concept studies (Corti et al., 2016; Mire et al., 2013; Pascal et al., 2018; Qiu et al., 2014; Thi et al., 2016) . To address this unmet public health need, we developed a two-antibody cocktail, MBP134 AF , with demonstrable activity against all known ebolaviruses (Wec et al., 2019) , including the ''pre-emergent'' agent Bombali virus recently discovered in molossid bats in Sierra Leone (Goldstein et al., 2018) . MBP134 AF , comprising the human broadly neutralizing antibodies (bNAbs) ADI-15878 AF and ADI-23774 AF (Wec et al., 2019) , was selected after a systematic process including the assessment and/or optimization of multiple mAbs and their combinations for potency and breadth, Fc effector functions via glycan engineering, and in vivo efficacy in rodent models of EBOV and SUDV infection (Wec et al., 2019) . ADI-15878 AF and ADI-23774 AF both target unique, non-overlapping epitopes on the ebolavirus glycoprotein (GP), neutralize both the extracellular and endosomally cleaved forms of GP, and lack crossreactivity against the secreted GP isoform (sGP) that is abundant in the plasma of infected individuals (Bornholdt et al., 2016; Wec et al., 2017) . The exceptional potency of MBP134 AF against guinea pig-adapted EBOV and SUDV (Wec et al., 2019) warranted continued evaluation in the ferret and nonhuman primate (NHP) large-animal models of ebolavirus challenge to assess its clinical potential. (B) qRT-PCR measuring average copies of EBOV/Makona genomic equivalents per mL of whole blood (GEQ/mL) from animals treated on day 2 and 5 (orange) and day 3 and 6 (green) p.i. (C) Infectious EBOV/Makona measured via plaque assays (PFU/mL) present in the blood of animals treated on day 2 and 5 (orange) or day 3 and 6 (green). (D) Survival curves for ferrets challenged with SUDV/Gulu and treated with 15-mg (green) or 5-mg (blue) doses of MBP134 AF on day 3 and 6 p.i. (E) The average GEQ/mL of SUDV/Gulu present in the blood of animals treated with 15-mg (green) or 5-mg doses (blue).
(F) SUDV/Gulu viremia present in the blood of animals treated with 15-mg (green) or 5-mg (blue) doses from (D). (G) Survival curves for ferrets challenged with BDBV/But-811250 and treated with 15-mg (green) or 5-mg (blue) doses of MBP134 AF on day 3 and 6 p.i. (H) The average GEQ/mL of BDBV/But-811250 from animals treated with two 15-mg (green) or 5-mg doses (blue). (I) Viremia (PFU/mL) present in the blood of animals treated with two 15-mg (green) or 5-mg doses (blue) from (G) . LOD, limit of detection. (Cross et al., 2016 (Cross et al., , 2018 Kozak et al., 2016) . Ferrets challenged intranasally with a lethal dose of EBOV/Makona received two 15-mg doses of MBP134 AF 3 days apart, with the treatment initiated on either day 2 (ferrets (F) The platelet counts for the cohort show severe thrombocytopenia in the control animals p.i. By contrast, animals receiving MBP134 AF rapidly recovered and displayed little or no signs of thrombocytopenia. Data are represented as mean ± SD. (G) The graphed CRP levels show NHP-3 and NHP-7 suffered from acute inflammation as a result of EVD prior to MBP134 AF treatment. (H) The ALT levels from each animal are shown; NHP-3 and NHP-8 demonstrated signs of advanced EVD that were alleviated post-treatment. (I) AST levels for all the challenged animals showed initial signs of liver damage resultant of EVD. Samples from NHP-8 in particular show a significant spike in AST levels that returned to baseline post-treatment. Legend for graphs in top right-hand corner; LOD, limit of detection. Expression in the CHOK1-AF platform greatly enhanced ADNP activity over the other expression platforms likely do to the more uniform heavy-chain glycosylation propensity offered by the CHOK1-AF stable pools over transient expression of the antibodies within plants. The formula for calculating the phagocytic score is described in the STAR Methods. The anti-human immunodeficiency virus GP120 mAb, 2G12, is utilized here as an irrelevant negative control mAb (Trkola et al., 1996) Figure 1A ). MBP134 AF fully protected from lethal challenge in both treatment groups and cleared viremia even in ferrets 5-8, which showed signs of active infection by RT-PCR prior to treatment (Figures 1B and 1C) . Similarly, administration of two 15-mg doses of MBP134 AF on days 3 and 6 (ferrets 1-4) afforded complete protection in ferrets challenged with lethal doses of SUDV/Gulu ( Figure 1D ) or BDBV/But-811250 ( Figure 1G ) and inhibited viral replication ( Figures 1E, 1F , 1H, and 1I). Because SUDV/Gulu and BDBV/But-811250 have been shown to be less virulent in ferrets than EBOV/Makona, with a relatively delayed time to peak viremia (Cross et al., 2016) , we next evaluated MBP134 AF in a lower dose-sparing treatment course of two 5-mg doses given on days 3 and 6 p.i. In this treatment group, ferrets 5-8 challenged with SUDV/Gulu displayed high levels of viremia and uniformly succumbed to disease by day 11 p.i. (Figures 1D-1F ). By contrast, ferrets 5-8 challenged with BDBV/But-811250 (characterized by the slowest onset of viremia; Cross et al., 2016) were protected by the two 5-mg dose regimen, with reversion of viremia in some animals ( Figures 1G-1I ). In summary, MBP134 AF conveys full protection to ferrets challenged with ebolaviruses from three divergent species.
A Single 25-mg/kg Dose of MBP134 AF Protects NHPs Challenged with EBOV/Kikwit We next evaluated the MBP134 AF cocktail's efficacy in the goldstandard NHP model of EBOV challenge. Ten rhesus macaques were randomized into two treatment groups, NHPs 1-4 and NHPs 5-8, and a PBS control group of two animals, and then challenged intramuscularly (i.m.) with 1,000 plaque-forming units (PFUs) of the Kikwit variant of EBOV (EBOV/Kikwit). NHPs 1-4 received a single intravenous (i.v.) 25-mg/kg dose of MBP134 AF on day 4 p.i., whereas NHPs 5-8 received a more conservative two-dose regimen of 50 mg/kg then 25 mg/kg on days 4 and 7 p.i., respectively. Remarkably, the single 25-mg/kg dose of MBP134 AF completely reversed the onset of EVD and protected NHPs 1-4 from a lethal EBOV/Kikwit exposure ( Figure 2A ). All animals in this study were confirmed to have had an active EBOV/ Kikwit infection via RT-PCR (10 7 -10 11 viral genome equivalents per mL [GEQ/mL]) and plaque assay (10 3 -10 6 PFU/mL) prior to treatment on day 4 p.i. (Figures 2B and 2C ). These high levels of viremia could nonetheless be reversed by MBP134 AF treatment-viremia in animals from both treatment groups fell below the limit of detection in the plaque assay by day 7 p.i. and in the RT-PCR assay by day 14 p.i. (Figures 2B and 2C ). Fever was detected in control animals and in three out of four animals in each treatment group at the time of the first MBP134 AF dosing; however, all treated animals returned to normal body temperature by day 10 p.i. Treated animals also maintained substantially lower clinical scores and reduced grade of thrombocytopenia compared to control NHPs ( Figures 2D-2F ). Two animals, NHP-3 and NHP-8, showed significant signs of EVD-induced liver injury prior to treatment, with elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and a third animal, NHP-7, displayed significant increases in C-reactive protein (CRP) levels. These and other hallmarks of EVD were significantly reduced post-treatment with MBP134 AF by day 10 p.i. ( Figures 2D-2I , S1, and S2). Thus, the pan-ebolavirus MBP134 AF cocktail could potently reverse the course of EVD and deliver complete therapeutic protection in NHPs following a lethal EBOV/Kikwit challenge with a single dose of only 25 mg/kg. MBP134 AF Produced from CHOK1-AF Cells Is Therapeutically Equivalent to the Plant-Produced MBP134 AF In the experiments described above, MBP134 AF was produced using a Nicotiana benthamiana (tobacco) plant-based expression system (Marillonnet et al., 2005; Zeitlin et al., 2011) . However, because the manufacturing infrastructure for Nicotiana-based products is still limited, we sought to transition MBP134 AF to the well-established Chinese hamster ovary (CHO) cell production platform. Accordingly, we expressed MBP134 AF in a GDP-fucose transporter SLC35C1-knockout cell line (CHOK1-AF), which maintains the afucosylated state of MBP134 AF . Comparative studies indicated that CHOK1-AF-produced MBP134 AF is comparable or even surpasses its plant-produced counterpart in neutralization potential (data not shown), Fc effector functions relevant to this cocktail's antiviral potency ( Figure 3) , and protective efficacy in guinea pigs ( Figure 4 ). Therefore, the Nicotiana-and CHO-produced MBP134 AF products are functionally equivalent. Accordingly, all remaining experiments described herein were performed with CHOK1-AF-expressed MBP134 AF , the manufacturing system being employed for its clinical development. Figure 4 . MBP134 AF Produced from CHOK1-AF Cells Is Therapeutically Equivalent to the Plant-Produced MBP134 AF (A) Hartley guinea pigs were divided into eight treatment groups and given a 5-mg total dose of CHO or plant-produced MBP134 AF on day 4, 5, 6, or 7 p.i. Animals receiving MBP134 AF treatment on day 4 or 5 p.i. showed equivalent and/or significant levels of protection, while all animals treated on day 6 or 7 succumbed to SUDV/Boniface infection with no detectable delay to death when compared to the PBS-treated controls. (B) Weight loss curves from animals treated with CHO or plant-produced MBP134 AF display equivalent weight change trends. Data are represented as mean ± SD. (C) The viral titers (PFU/mL) in blood samples taken from each animal immediately prior to treatment are graphed. The data suggest MBP134 AF produced from either platform equivalently protected animals with <10 5 PFU/mL of infectious virus, with reduced efficacy in animals that showed viral loads >10 5 PFU/mL. Data are represented as mean ± SD. (Ellis et al., 1978; unpublished data) . Twelve animals were randomized into two treatment groups, NHPs 1-4 and NHPs 5-8, and one control group, PBS controls 1-4. On day 5 p.i., NHPs 1-4 and 5-8 received single 7.5-mg/kg and 25-mg/kg doses of MBP134 AF , respectively. Both doses of MBP134 AF provided full protection from SUDV disease and all MBP134 AF -treated animals became viremia-negative by day 8 p.i. (Figures 5A-5C ). MBP134 AF -treated animals displayed little to no clinical signs of disease in contrast to the control animals-half of the latter succumbed to infection ( Figure 5D ). Importantly, all of the animals in the blinded MBP134 AF cohort registered a fever prior to receiving MBP134 AF on day 5 p.i. ( We next determined the protective efficacy of MBP134 AF against lethal BDBV/But-811250 challenge in the cynomolgus macaque model of infection (Burk et al., 2016; Mire et al., 2013) . We chose to treat animals at day 7 p.i. with MBP134 AF because previous reports indicated that they were already viremic and showing signs of EVD at this time point . We reasoned that treatment under these post-exposure conditions would afford a rigorous evaluation of MBP134 AF 's ability to reverse advanced EVD caused by BDBV. Accordingly, a cohort of 9 animals was exposed to 1,000 PFU (i.m.) of BDBV/But-811250. Six randomly selected animals received a single 25-mg/kg i.v. infusion of MBP134 AF on day 7 p.i. and three received PBS. This single dose of MBP134 AF provided significant levels of protection (p value of 0.006 or 0.0108 if calculated including the historical controls; Mire et al., 2013) , with only one animal succumbing to infection. By contrast, uniform lethality was observed in the PBS control group (Figure 6A ). Prior to MBP134 AF treatment on day 7 p.i., animals registered elevated clinical scores and body temperatures, viremia as high as 10 11 GEQ/mL or 10 7 PFU/mL, and EVDinduced thrombocytopenia (Figures 6B-6F ). By the next blood collection point on day 10 p.i., five of the six animals that received MBP134 AF had no detectable infectious BDBV in the blood, and clinical scores were reduced to basal levels by day 12 p.i., a complete reversion of infection and disease. The single treated animal that succumbed, NHP-5, did not have the highest viral load but showed acute liver injury prior to treatment, displaying the highest ALP, ALT, and AST levels of all the animals in the cohort on day 7 p.i. prior to receiving its dose of MBP134 AF (Figures 6G-6I , S4, and S5). Given the recovery of two animals (NHP-4 and NHP-6) harboring higher viral loads prior to treatment, we postulate that NHP-5's liver injury prior to treatment was too severe for it to recover despite receiving MBP134 AF . In summary, MBP134 AF demonstrates significant levels of protection and reversion of BDBV disease in cynomolgus macaques.
A B C

DISCUSSION
Prior to this work, the development of mAb-based therapeutics has typically followed a ''one bug, one drug'' paradigm under the premise that mAbs with broad activity would not be as potent as those with clade-specific activity (Vigant et al., 2015) . Here, we demonstrate that MBP134 AF , a pan-ebolavirus immunotherapeutic comprising two bNAbs, ADI-15878 AF and ADI-23774 AF , could not only protect NHPs against every ebolavirus known to cause human disease outbreaks but could do so at an unparalleled single 25-mg/kg dose. Importantly, MBP134 AF was effective against multiple ebolaviruses from different species, suggesting that it will retain activity in the face of both intra-and inter-species sequence divergence, a result of its targeting highly conserved epitopes in GP. Indeed, as shown in the companion paper (Wec et al., 2019) , MBP134 AF recognizes and neutralizes entry by the newly identified Bombali virus glycoprotein. Further studies exploring 7.5 mg/kg or lower i.v. doses of MBP134 AF could open the door to intramuscular or subcutaneous delivery via autoinjector, allowing for rapid and efficient drug administration to patients and reducing the burden on healthcare workers in the field and EBOV treatment units. The developmental path of MBP134 AF presents a model for the rapid design of next-generation antiviral immunotherapeutics targeting World Health Organization-priority pathogens.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
STAR+METHODS CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Larry Zeitlin (larry.zeitlin@mappbio.com) .
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
Vero female African grivet monkey kidney cells were obtained from American Type Culture Collection (ATCC) and maintained in highglucose Dulbecco's modified Eagle medium (DMEM; Thermo Fisher, Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA), 1% GlutaMAX (Thermo Fisher), and 1% penicillin-streptomycin (Thermo Fisher). Cells were maintained in a humidified 37 C, 5% CO2 incubator. Suspension adapted HEK293F (Thermo Fisher) were maintained in serum free Freestyle HEK293F expression medium (Thermo Fisher). Cells were maintained in a humidified 37 C, 8% CO2, 125 RPM shaking incubator. CHOK1-AF female Cricetulus griseus ovarian SLC35C1-knockout stably expressing 23774 AF or 15878 AF (Mapp Biopharmaceuticals) were maintained in BalanCD Growth A medium containing MSX. Cells were maintained in a 37 C, 5% CO2 140 RPM shaking incubator.
Culture of Primary Human Innate Immune Cells
Primary human neutrophils and NK cells from deidentified donors were cultured and maintained in RPMI1640 supplemented with 10% fetal bovine serum, L-Glutamine, and penicillin/streptomycin at 37C in a humidified incubator at 5% CO2 for the duration of the assays.
Ethics Statement for Primary Human Innate Immune Cells
Innate immune effector cells were isolated from fresh peripheral blood samples collected by the Ragon Institute or the MGH Blood bank from healthy human volunteers. All subjects signed informed consent and the study was approved by the MGH Institutional Review Board. Samples were collected from human adults older than 18 years of age, and were completely deidentified prior to use and thus, researchers were blinded to gender and age of donors.
Ferrets
Female ferrets were purchased from Marshall Farms. Six to eight month old animals weighing between 0.75-1 kg, were housed 2-3 per cage per study were used for in vivo challenge studies as previously described (Cross et al., 2016) .
Non-Human Primates
Male and female rhesus macaques and cynomolgus monkeys were purchased from PrimGen. Animals aged 3-8 years old (4-7.8 kg) were randomly assigned to treatment groups, with even distribution of male and female macaques. 
Guinea Pigs
Female Hartley guinea pigs were purchased from Charles River Laboratories (Wilmington, MA). Animals between 5-6 weeks old, weighing 350-450 g, were randomly split into groups of 3-6 for in vivo challenge studies.
USAMRIID Animal Welfare, Observation and Euthanasia Criterion
Animal studies were conducted under IACUC-approved protocols in compliance with the Animal Welfare Act, PHS Policy, and other applicable federal statutes and regulations relating to animals and experiments involving animals. USAMRIID is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC) and adhere to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council. Physical exams were also completed on blood collection days to assess the overall physical condition of the animals and disease progression. Cage side observations were completed at least once daily throughout the course of the experiment to assess the general disposition of each anima l and disease progression. Clinical scores for each animal were derived from cage side observations of awake animals and physical observations completed on anesthetized animals. Animals were assessed and given a cumulative score based on numerous behavioral and physical parameters, including responsiveness, petechial rash, temperature, weight change, gastrointestinal and renal output, anorexia, respiration, dehydration, and edema. Higher clinical scores indicate more severe signs of disease. Macaques determined to be moribund, in accordance with the USAMRIID Institutional Animal Care and Use Committee (IACUC) approved criteria, were promptly euthanized.
UTMB Animal Welfare, Observation and Euthanasia Criterion
All animal studies were conducted under a protocol approved by the University of Texas Medical Branch (UTMB) IACUC. IACUC approval of animal studies performed at UTMB are in compliance with the Animal Welfare Act, PHS Policy and other Federal statutes and regulations relating to animals and experiments involving animals. The facilities where this research was conducted are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and adhere to principles stated in the eighth edition of the Guide for the Care and Use of Laboratory Animals, National Research Council. All animals were monitored daily and scored for disease progression with an internal filovirus scoring protocol approved by the UTMB IACUC. The scoring changes measured from baseline included posture/activity level, attitude/behavior, food intake, respiration, and disease manifestations such as visible rash, hemorrhage, ecchymosis, or flushed skin. A score of R 9 indicated that an animal met criteria for euthanasia.
Authentic Filoviruses
The authentic filoviruses EBOV/Makona (Ebola virus/H.sapiens-tc/GIN/14/Makona-Gueckedou-C07) (Mire et al., 2015) , EBOV/ Kikwit (Ebola virus/H. sap-tc/COD/95/Kikwit-9510621) (Cross et al., 2016) , BDBV (BDBV/H.sapiens-tc/UGA/07/But-811250) (Cross et al., 2016) , SUDV/Gulu (Sudan virus/H.sapiens-tc/UGA/00/Gulu-200011676) (Thi et al., 2016) , SUDV/Boneface (Sudan virus/H. sap-gp-tc/SDN/1976/Boneface-USAMRIID111808) (Ellis et al., 1978) , Guinea pig-adapted SUDV/Boniface (SUDV-GPA) (Sudan virus/NML/C.porcellus-lab/SSD/1976/Nzara-Boneface-GP) (Wong et al., 2015) were used in this study.
METHOD DETAILS
Expression and Purification of MBP134 AF mAbs from DXTFT N. benthamiana Plants The transient expression and purification of ADI-23774 AF and ADI-15878 AF from N. benthamiana tobacco plant expression platform was performed as previously described .
Expression of ADI-23774 AF and ADI-15878 AF from CHOK1-AF Cell Lines CHOK1-AF cells stably expressing the ADI-23774 AF and ADI-15878 AF mAbs were generated as follows: a dual plasmid system containing expression cassettes for the heavy and light chains of the target mAb were co-transfected by chemical means into a modified CHOK1 host cell line. Stable selection was initiated by exchanging medium in the shake flask with growth medium containing MSX as a selection agent 24 hours post transfection. Upon recovery of the cells (3 weeks), a Research Cell Bank was created for further development. Enriched stable pools were created from the original transfected pool using ClonePix2 technology (Molecular Devices). A vial from an enriched pool of CHOK1-AF cells expressing ADI-23774 AF or ADI-15878 AF was removed from cryostorage, thawed, and resuspended in 30 mL of BalanCD Growth A medium containing MSX in a 125 mL shake flask. The newly thawed culture was placed in a shaking CO2 incubator set at 5% CO2 and 140 RPM. Over the next 14 days the culture was expanded to a final volume of 13L in multiple 5L shake flasks (Thomson) for production. Upon completion of the final expansion the culture was maintained in batch-mode for 10 days, after which the supernatant was clarified via filtration and subsequently sterile filtered (0.2 mm) into a 20L bioprocess bag (Thermo Fisher) prior to protein A purification.
Purification of ADI-23774 AF and ADI-15878 AF MBP134 AF mAbs, ADI-23774 AF and ADI-15878 AF , were purified using a GE MabSelect SuRe LX Protein A affinity chromatography column using an AKTA pure 150M3. The conditioned media were loaded onto the MabSelect column, washed with HyClone 1X PBS, then eluted using 0.1 M Acetic Acid containing 0.2 M L-Arginine, pH 2.9-3.0. Immediately post elution the mAbs were held at low pH for 3 hours as a viral inactivation step, then eluates were neutralized with 2 M Tris base to pH 7. Neutralized eluate was then filtered through Sartorius Sartobind Q SingleSep Mini filters for endotoxin and host-cell DNA removal and diafiltered against a formulation buffer (20 mM Citrate, 10 mM Glycine, 8% Sucrose, pH 5.5) using a GE AKTA flux 6 TFF system equipped with a Sartorius Sartocon Slice Disposable PESU Cassette (MWCO of 50 kDa). After diafiltration, the mAbs were concentrated using a Millipore Labscale TFF system equipped with a Sartorius Vivaflow 200 Cassette (MWCO of 50 kDa) to concentration of 25-30 mg/mL. Polysorbate-80 was added to 0.01% after the target mAb concentration was reached. The MBP134 AF mAb cocktail, consisting of ADI-23774 AF and ADI-15878 AF , was generated by mixing equal amounts, by protein mass, of the two mAbs.
UTMB Ferret Ebolavirus Challenge Studies
Female ferrets were housed and challenged intranasally as previously described (Cross et al., 2016) . Briefly, ferrets weighing between 0.75-1 kg were housed 2-3 per cage per study. Ferrets were anesthetized by intramuscular injection with a ketamine-acepromazine-xylazine cocktail prior to all procedures. Subjects were challenged intranasally with 1000 PFU of EBOV/Makona (n = 9), SUDV/Gulu (n = 9), and BDBV/But-811250 (n = 9), respectively. The treated ferrets received doses of MBP134 AF via intraperitoneal (IP) injection on days 2 and 5 or days 3 and 6. Ferrets challenged with EBOV/Makona and treated on days 2 and 5 were bled on either day 0, 2, 5, and 33 or at time of euthanasia, while those treated on days 3 and 6 were bled on days 0, 3, 6, and 33 or upon being euthanatized. Animals challenged with SUDV/Gulu or BDBV/But-811250 were bled on days 0, 3, 6, and 28 or upon being euthanatized.
UTMB EBOV/Kikwit NHP Challenge Study
Male and female rhesus macaques, ten in total, were challenged by intramuscular (IM) injection with 1,000 PFU of EBOV/Kikwit (actual dose: 988 PFU), isolate 199510621 from a 65-year-old female patient who had died on May 5 th 1995. Animals (n = 4/group) were treated IV with either a single 25 mg/kg dose on day 4 or a two-dose regimen of 50 mg/kg (on day 4) and 25 mg/kg (on day 7) of MBP134 AF produced in DXTFT N. benthamiana plants. Control animals (n = 2) received a pseudo IV treatment of PBS. Blood samples were collected from experimental macaques and control macaques on days 0, 4, 7, 10, 14, 21, and 28 p.i. The EBOV/Kikwit plaque assays and real-time qPCR analyses from whole blood and tissue samples were performed as previously described (Geisbert et al., 2009; Matassov et al., 2017) .
USAMRIID SUDV/Boniface Guinea Pig Challenge Study
Female Hartley guinea pigs (350-450 g) were randomly assigned to experimental groups and challenged IP with a target dose of 1000 PFU of guinea pig adapted SUDV (Wong et al., 2015) in 0.5 mL of MEM. Groups (n = 3-6) of guinea pigs were treated with 5mg of MBP134 AF -N (plant expressed) or MBP134 AF -CHO via IP injection on days 4 (n = 6), 5 (n = 3), 6 (n = 5), or 7 (n = 5) p.i. Control guinea pigs (n = 6) were given an equal volume of vehicle on day 4 p.i. Blood was collected from each animal just prior to antibody delivery to determine viremia. Animals were observed for clinical signs of disease, survival, weight change and temperature change for 14 days, while survival was monitored for an additional 11 days.
USAMRIID SUDV/Boniface Rhesus Macaque Study
Male and female rhesus macaques (4-7.8 kg) were randomly assigned to treatment groups, with even distribution of male and female macaques, and study personnel remained blinded to all treatment groups. Macaques were inoculated via IM injection with a target dose of 1000 pfu (actual dose: 1750 pfu) of SUDV/Boniface. Experimental macaques were treated IV with a cocktail of CHOK1-AF produced MBP134 AF . Control macaques (n = 2) received an equal volume to weight ratio of vehicle IV on day 5 p.i. Blood samples were collected from experimental macaques and control macaques on days 0, 3, 5, 8, 11, 14, 21, and 28 p.i. Additional control animals (n = 2, PBS Control-3 and PBS Control-4) from a separate experimental cohort run concurrently received an equal volume to weight ratio of vehicle IV on days 4 and 6 p.i. These animals were bled on days 0, 4, 6, 8, 11, 14, 21, and 28 p.i.
USAMRIID Hematology and Serum Biochemistry from the SUDV/Boniface NHP Study
Phlebotomy was performed while the animals were anesthetized, and blood was collected from the femoral vein using a venous blood collection system (Becton Dickinson). Hematological values for blood samples collected in tubes containing EDTA were determined using a Coulter Ac-T diff analyzer (Beckman Coulter). Serum chemistry was analyzed using Piccolo General Chemistry 13 reagent discs and a Piccolo Xpress point-of-care blood analyzer (Abaxis).
USAMRIID SUDV/Boniface Plaque Assays
Serial dilutions of serum were prepared in modified Eagle medium with Earle's balanced salts and nonessential amino acids supplemented with 5% DFBS, 2mM L-glutamine and 1% gentamicin. Then 200 ml from each dilution was inoculated onto Vero E6 cell monolayers withinn 6-well plates. After adsorption for 1 hour at 37 C, 5% CO 2 , and 80% humidity, the cell monolayers were overlaid with a mixture of 1 part 1% agarose (Seakem) and 1 part 2X Eagle basal medium, 30mM HEPES buffer, and 5% DFBS. After incubation at 37 C, 5% CO 2 , and 80% humidity for 8 days, a second overlay, supplemented with 5% neutral red, was then added. Plaques formed by infectious SUDV/Boniface virus were then counted 24 hours later and titers were expressed as PFU/mL.
